CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress.
“We look forward to highlighting how blood centers around the world are leveraging INTERCEPT technology to strengthen blood safety, improve operational efficiency and enhance patient care,” said Christian Boutemy, vice president, international commercial operations at Cerus. “This year’s abstracts reflect the growing body of evidence supporting the INTERCEPT Blood System, alongside valuable real-world experiences from blood centers across Asia. The presentations showcase innovations intended to help optimize operations, including reduced processing times with the LED-based INT200 illuminator and inventory management advantages associated with extended platelet shelf-life, as demonstrated by experience from Thailand. Importantly, an abstract from China draws attention to persistent bacterial contamination risks in platelet components and reinforces the value of a proactive pathogen-inactivation strategy in one of the world’s largest transfusion markets.”
The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Malaysian Time (MYT – UTC+8).
Oral Presentation
-
Sunday, June 21, 2026, 12:45–13:45 – Cerus symposium
Pathogen Inactivation: The Proactive Choice to Improve Blood Safety - Chair: Pimpun Kitpoka, Thailand
-
Presentations:
- Blood safety – Miles to go, before we sleep – Dr. Albert Farrugia
- INTERCEPT: Unmatched evidence and Proven patient benefits – Dr. Richard Benjamin
Poster Presentations
Poster-Session: Monday, June 22, 2026, 17:15–18:45 hours
Select Posters of Interest
- P363 – Preserved Fibrinogen Recovery and Stability of Low Plasma Volume Pathogen Reduced Cryoprecipitated Fibrinogen Complex. M. Gatmaitan, A. Paez, Y. Luo et al
- P373 – Reduction in Compound Adsorption Device Exposure Time for Pathogen Inactivated Platelet Components Treated With Amotosalen and an LED-Based Illumination Device. B. Dillon, A. Bernal, S. Crawford et al
- P370 – Introduction of Pathogen-Reduced Double-Dose Apheresis Platelets in a Tertiary Teaching Hospital in Thailand – Impact on Component Characteristics and Clinical Use. S. Khuenkham, N. Neeranatpaiboon, M. Picard-Maureau et al
- P376 – Amotosalen/UVA Inactivation of TTI-Associated Bacteria in Platelet Components. M. Krath, A. Engelhaupt, P. Nahata et al
- P478 – Bacterial Contamination of Platelet Concentrates in China. H. Weidong, C. Yuanfeng, X. Junfeng et al
The full program of Cerus-related abstracts can be found here: https://interceptbloodsystem.com/wp-content/uploads/2026/06/2026_ISBT_AbstractBook.pdf.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.
Contacts
Tim Lee – Head of Investor Relations
Cerus Corporation
[email protected]
925-288-6128
